-
×èòàòåëü Íåäóã.Ðó
Óâàæàåìàÿ Ãàëèíà Àôàíàñüåâíà, ÿ ñíîâà ê Âàì çà ïîìîùüþ. Íå çíàþ, ïðàâäà, ñìîæåòå ëè Âû ÷òî-òî ïîñîâåòîâàòü, âåäü ýòî íå ñîâñåì Âàø âîïðîñ, íî Âû âåäü âñå çíàåòå.
Ó ìåíÿ îáíàðóæèëè àäåíîìó îêîëîóøíîé ñëþííîé æåëåçû 2õ2,6ñì.  ïîíåäåëüíèê ëîæóñü â êëèíèêó ×ËÕ (7 ýòàæ).
 ÷åòâåðã - îïåðàöèÿ. Ãîâîðÿò äîâîëüíî ñëîæíàÿ, ïîä îáùèì íàðêîçîì. Áîþñü óæàñíî.
Äîêòîð ñêàçàë, ÷òî ïîñëå óäàëåíèÿ àäåíîìû, íóæíî îòëîæòü áåðåìåííîñòü íà ãîä, îáúÿñíèâ ýòî òåì, ÷òî ïðè áåðåìåííîñòè ïðîèñõîäèò ãîðìîíàëüíûé âçðûâ è ýòî ìîæåò ñïðîâîöèðîâàòü ðåöèäèâ îïóõîëè. Ïî÷åìó èìåííî íà ãîä, âåäü ïðè áåðåìåííîñòè äàæå ÷åðåç 10 ëåò âñå-ðàâíî áóäåò ýòîò ñàìûé "âçðûâ"? ×òî Âû äóìàåòå ïî ýòîìó âîïðîñó? Äëÿ ìåíÿ ýòî âàæíî, òàê êàê ÿ è òàê âûæèäàëà 1,5 ãîäà ïîñëå ïîòåðè ðåáåíêà.
È ÷òî Âû âîîáùå äóìåòå ïî ïîâîäó ïóñêîâîãî ìîìåíòà äëÿ âîçíèêíîâåíèÿ ïîäîáíûõ îïóõîëåé? Î÷åíü èíòåðåñíî Âàøå ìíåíèå.
Ñïàñèáî çàðàíåå çà îòâåò. Ñ óâàæåíèåì. Åâãåíèÿ.
-
×èòàòåëü Íåäóã.Ðó
Óâàæàåìàÿ Åâãåíèÿ!
Ïîçâîëüòå âûñêàçàòü ñâîå ìíåíèå, ïîêà îæèäàåòå îòâåò îò Ãàëèíû Àôàíàñüåâíû.
Ðåöèäèâ ïëåéîìîðôíîé àäåíîìû çàâèñèò ñêîðåå îò îáüåìà îïåðàöèè: òàê ïðè âûëóùèâàíèè àäåíîóçëà äîñòàòî÷íî âûñîê 20-45%, òîãäà êàê ïîñëå òîòàëüíîãî óäàëåíèÿ - âñåãî 1-5%. È õîòÿ åñòü ðàáîòû, îïèñûâàþùèå ðàçíóþ ýêñïðåññèþ ðåöåïòîðîâ ê ïîëîâûì ãîðìîíàì ìåæäó îïóõîëåâîé è íîðìàëüíîé òêàíÿìè, íî ïîêà íè áåðåìåííîñòü, íè äð. ãîðìîíàëüíûå "âçðûâû" íå áûëè çàìå÷åíû êàê ïðîâîöèðóþùèå ôàêòîðû:
Glas AS, Hollema H, Nap RE, Plukker JT. Expression of estrogen receptor, progesterone receptor, and insulin-like growth factor receptor-1 and of MIB-1 in patients with recurrent pleomorphic adenoma of the parotid gland. Cancer. 2002 Apr 15;94(8):2211-6.
À âîò íåïîëíîå óäàëåíèå ïîõîæå ìîæåò ïîâëèÿòü íà ðèñê ðåöèäèâà:
The extended multifocal distribution of tumor recurrences after insufficient resection of pleomorphic adenoma (most often after enucleation) can explain a high incidence of further recurrences. Therefore, a total parotidectomy including removal of surrounding fat tissue seems to be appropriate for the initial treatment of recurrent pleomorphic adenoma.
Èç Stennert E, Wittekindt C, Klussmann JP, Arnold G, Guntinas-Lichius O. Recurrent pleomorphic adenoma of the parotid gland: a prospective histopathological and immunohistochemical study. Laryngoscope. 2004 Jan;114(1):158-63.
-
×èòàòåëü Íåäóã.Ðó
Óâàæàåìàÿ Ïàðê, çíàþ ÿ äàëåêî íå âñå, è ïðåêðàñíî, ÷òî êîëëåãè ïîìîãàþò. Íó à ñ 7-ãî ýòàæà ïðè ñëó÷àå çàãëÿíèòå ê íàì íà 6-îé..
-
×èòàòåëü Íåäóã.Ðó
Óâàæàåìûé äîêòîð Vad, ñïàñèáî çà îòâåò. Ïðàâäà, ÿ íå íàñòîëüêî õîðîøî çíàþ àíãëèéñêèé, ÷òîáû ïîëíîñòüþ ïîíÿòü ñìûñë âòîðîé öèòàòû. Ïîÿñíèòå, ïîæàëóéñòà.
Ìíå, êàê ÿ ïîíÿëà. áóäóò äåëàòü ñóáòîòàëüíóþ ðåçåêöèþ, à íå òîòàëüíóþ. Íåò ëè ó Âàñ èíôîðìàöèè î âåðîÿòíîñòè ðåöèäèâà ïðè òàêîì âèäå îïåðàöèè?
-
×èòàòåëü Íåäóã.Ðó
Óâàæàåìàÿ Ãàëèíà Àôàíàñüåâíà! Ñïàñèáî çà ïðèãëàøåíèå. Áûëà áû ñ÷àñòëèâà ñ Âàìè ïîçíàêîìèòüñÿ. À íà ïðåäìåò ÷åãî ìû áóäåì îáùàòüñÿ?
Ñ óâàæåíèåì, Åâãåíèÿ.
-
×èòàòåëü Íåäóã.Ðó
Ðåêîìåíäóþ îáðàòèòüñÿ ñ âîïðîñîì íà êîíñóëüòàòèâíûé Ðóñîíêîôîðóì â ðàçäåë "îïóõîëè ãîëîâû è øåè" (http://pacient.oncoforum.ru/viewforum.php?f=12) ê äîêòîðó Í.Â. Ïàíêèíîé.
-
×èòàòåëü Íåäóã.Ðó
Óâàæàåìàÿ Åâãåíèÿ!
Îáüåì îïåðàöèè åùå è çàâèñèò îò ðàñïðîñòðàíåííîñòè îïóõîëè â æåëåçå: îáû÷íî ñóáòîòàëüíàÿ ðåçåêöèÿ òàêæå äàåò íå âûøå 5% ðåöèäèâîâ.
Ñóòü ïîñëåäíåé ôðàçû: ïðè ÐÅÖÈÄÈÂÀÕ (à íå ïåðâè÷íîé ðåçåêöèè!) àäåíîìû òîòàëüíóþ ðåçåêöèþ, âêëþ÷àÿ îêðóæ. æèðîâ. òêàíü, ñëåäóåò ñ÷èòàòü íàèáîëåå ðàöèîíàëüíîé òàêòèêîé ëå÷åíèÿ.
-
×èòàòåëü Íåäóã.Ðó
Ñïàñèáî, äîêòîð, Âû ìåíÿ íåìíîãî óñïîêîèëè, òàê êàê ìàíäðàæ æóòêèé. Ïîñëå òîãî, êàê ïðî÷ëà Âàø ïðåäûäóùèé îòâåò î òîì, ÷òî òîëüêî òîòàëüíîå óäàëåíèå äàåò ãàðàíòèþ îò ðåöèäèâà, îáðàòèëàñü ê õèðóðãó ñ ïðîñüáîé óäàëèòü âñþ æåëåçó. Îòâåò áûë, ÷òî ïðè ýòîì ïðîèñõîäèò îáåçîáðàæèâàíèå ëèöà è êðîìå òîãî ýòî íå ïîëîæåíî "ïî çàêîíó".
Òî, ÷òî Âû íàïèñàëè òåïåðü íàìíîãî ðàäîñòíåå. Ýòî òîæå äîñòîâåðíûå äàííûå?
Ïðàâäà, ñêàçàëè, ÷òî ïîñëåîïåðàöèîííûé ïàðåç ïðàêòè÷åñêè íåèçáåæåí, òàê êàê âî âðåìÿ îïåðàöèè ïðîèñõîäèò âûäåëåíèå íåðâà è íàðóøàåòñÿ ïèòàíèå + ïîñëåîïåðàöèîííûé îòåê îêðóæàþùèõ òêàíåé.
Ñïàñèáî.
-
×èòàòåëü Íåäóã.Ðó
Óâàæàåìàÿ Ðark!
Ïî äàííûì îäíîé êëèíèêè â Ãåðìàíèè, êîòîðàÿ íà ïðîòÿæåíèè 8 ëåò ÷àñòè÷íî èëè ïîëíîñòüþ óäàëÿëà æåëåçó âìåñòå ñ àäåíîìîé ïî ïàðåçàì ìîæåò áûòü ñëåäóþùàÿ ñòàòèñòèêà (170 ïàöèåíòîâ): ÷àñòè÷íûé âðåìåííûé ïàðåç - â 25% ñëó÷àåâ, ïîëíûé âðåìåííûé ïàðåç - 3%. ×àñòè÷íûé ïîñòîÿííûé ïàðåç 5%, ïîëíûé ïîñòîÿííûé - íèêîãäà.
Eur Arch Otorhinolaryngol. 2004 Mar;261(3):143-6.
Pleomorphic adenoma of the parotid gland: a 13-year experience of consequent management by lateral or total parotidectomy.
Guntinas-Lichius O, Kick C, Klussmann JP, Jungehuelsing M, Stennert E.